AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
While AbbVie’s Humira still holds the crown for the best-selling non-Covid drug last year, the Big Pharma has its eyes on Humira’s potential successor. Scratch that, successors.
AbbVie CEO Rick Gonzalez told investors and analysts on the pharma’s Q4 call this morning that AbbVie expects to add several new indications to Skyrizi and Rinvoq’s “list of approved uses” over the next few months. For Skyrizi, they got the FDA’s OK a few weeks ago to use the drug for psoriatic arthritis — and they’re also looking for the thumbs up from the agency on Crohn’s disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.